InvestorsObserver
×
News Home

Is Jazz Pharmaceuticals PLC (JAZZ) Stock About to Get Hot Wednesday?

Wednesday, November 30, 2022 03:41 PM | InvestorsObserver Analysts

Mentioned in this article

Is Jazz Pharmaceuticals PLC (JAZZ) Stock About to Get Hot Wednesday?

Jazz Pharmaceuticals PLC (JAZZ) stock has gained 2.38% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Jazz Pharmaceuticals PLC has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on JAZZ!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With JAZZ Stock Today?

Jazz Pharmaceuticals PLC (JAZZ) stock is trading at $156.86 as of 3:41 PM on Wednesday, Nov 30, a rise of $1.21, or 0.78% from the previous closing price of $155.65. The stock has traded between $155.22 and $157.45 so far today. Volume today is low. So far 314,723 shares have traded compared to average volume of 490,058 shares.

More About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Click Here to get the full Stock Report for Jazz Pharmaceuticals PLC stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App